Advertisement

Topics

Courtagen Receives Notice of Allowance for a Genetically Targeted Pain Therapy Patent in the U.S.

08:47 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Patent targets personalized medicine approach matching genetic markers for chronic pain with therapeutic drugs, including the cannabis-derived compound cannabidiol Courtagen Life Sciences, Inc., an innovative endocann...

Other Sources for this Article

Courtagen Life Sciences
Mike Catalano, 877-395-7608
press@courtagen.com

NEXT ARTICLE

More From BioPortfolio on "Courtagen Receives Notice of Allowance for a Genetically Targeted Pain Therapy Patent in the U.S."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...